Authors
Tian Liu, Kewei Liu, Yongying Hou, Zhaole Chu, Jinyang Li, Mengting Sun, Linyu Wu, Qin Liu, Zhili Zhou, Qiaoqiao Zhang, Bin Wang, Qinglian Wen, Xingwei Wang, Jiang Min
Published in
BMC cancer. Volume 26. Issue 1. Oct 21, 2026. Epub Oct 21, 2026.
Abstract
Sorafenib remains a standard therapy for hepatocellular carcinoma (HCC), but intratumor heterogeneity and drug resistance limit its efficacy. To identify resistance-associated genes, we performed a CRISPR activation screen and integrated results with TCGA and GTEx data. Using univariate Cox and LASSO regression, we constructed a five-gene (AKR1B15, BMF, GBA, GINS2, SMC2) sorafenib sensitivity-related prognostic signature. In the TCGA-LIHC training cohort (n = 371), patients with high-risk scores showed significantly worse overall survival and reduced sorafenib sensitivity, which was validated in the ICGC-US cohort. High risk scores also correlated with adverse clinicopathological features. Drug perturbation Gene Set Enrichment Analysis (dpGSEA) identified ciclesonide as a potential sensitizer to sorafenib. Cell viability assays and a subcutaneous xenograft model confirmed that ciclesonide enhanced the antitumor efficacy of sorafenib. RNA sequencing further suggested that this effect may be mediated through regulation of the cell cycle pathway. Collectively, the sorafenib DS-related prognostic signature may serve as an independent prognostic biomarker and predictor of sorafenib sensitivity in HCC, while the combination of sorafenib and ciclesonide represents a promising strategy to improve targeted therapy.
PMID:
43015682
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0